# Re-Treatment Study of Probuphine in Opioid Addiction

> **NCT01262261** · PHASE3 · COMPLETED · sponsor: **Titan Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- Opioid Dependency

## Interventions

- **DRUG:** Probuphine (buprenorphine implant)

## Key facts

- **NCT ID:** NCT01262261
- **Lead sponsor:** Titan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262261, "Re-Treatment Study of Probuphine in Opioid Addiction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01262261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*